S&P 500
6,000.36
+1.0%
+$61.06
DJI
42,762.87
+1.0%
+$443.13
NASDAQ
19,529.95
+1.2%
+$231.50
Bitcoin
104,474.00
+3.0%
+3,069.10
AAPL
$204.23
+1.8%
+$3.60
AMZN
$213.68
+2.8%
+$5.77
GOOG
$174.93
+3.0%
+$5.12
META
$698.00
+2.0%
+$13.38
MSFT
$470.38
+0.6%
+$2.70
NVDA
$141.76
+1.3%
+$1.77
TSLA
$295.66
+3.8%
+$10.96

Alumis (NASDAQ: ALMS)
$3.60
(7.5%)
$0.25
Price as of June 6, 2025, 3:56 p.m. ET
Alumis Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Alumis Company Info
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.
News & Analysis
No articles found.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.